FDA approves AstraZeneca’s Imfinzi in combination with chemotherapy for resectable early-stage non-small cell lung cancer

In the combination therapy, Imfinzi is administered in combination with neoadjuvant chemotherapy for non-small cell lung cancer before surgery, and then Imfinzi is administered as a monotherapy after surgery.